TFX TELEFLEX INC
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 96943 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY20.9%
TTM net income YoY192.9%
TTM EPS YoY212.3%
Revenue 3-yr CAGR-8.6%
Net income 3-yr CAGR-9.0%
Margins
Gross margin58.3%
Operating margin9.4%
Net margin13.5%
FCF margin3.9%
EBITDA margin18.7%
Returns
ROE8.3%
ROA4.3%
ROIC (approx.)3.8%
Asset turnover0.32x
Leverage & solvency
Liabilities / assets45.0%
Debt / equity0.46x
Current ratio2.01x
Interest coverage2.06x
Cash quality & payout
Operating cash flow / net income0.47x
Accruals ratio2.3%
Payout ratio19.3%
Capex / revenue2.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.99B | $1.70B |
| Cost of revenue | $871.96M | $662.16M |
| Gross profit | $1.12B | $1.04B |
| R&D expense | $144.78M | $109.02M |
| SG&A expense | $720.17M | $674.52M |
| Operating income | $118.37M | $103.65M |
| Interest expense | $100.22M | $83.51M |
| Pretax income | $24.55M | $26.29M |
| Income tax | -$33.98M | -$30.90M |
| Net income | -$905.64M | $69.67M |
| EBITDA | $296.11M | $265.19M |
| EPS (basic) | -20.30 | 1.49 |
| EPS (diluted) | -20.25 | 1.48 |
| Dividends declared per share | 1.36 | 1.36 |
| Weighted avg. shares (diluted) | 44.72M | 47.09M |
| Balance sheet | ||
| Cash & equivalents | $378.56M | $247.85M |
| Receivables | $345.58M | $226.73M |
| Inventory | $404.39M | $306.77M |
| Current assets | $1.94B | $1.47B |
| PP&E, net | $498.28M | $308.46M |
| Goodwill | $2.31B | $1.99B |
| Intangibles | $1.52B | $1.35B |
| Total assets | $6.95B | $7.10B |
| Current liabilities | $762.03M | $649.36M |
| Short-term debt | $100.00M | $100.00M |
| Long-term debt | $2.54B | $1.56B |
| Total debt | $2.64B | $1.66B |
| Total liabilities | $3.82B | $2.82B |
| Shareholders' equity | $3.12B | $4.28B |
| Net debt | $2.26B | $1.41B |
| Cash flow statement | ||
| Operating cash flow | $96.68M | $301.88M |
| Capital expenditure | $95.24M | $90.44M |
| Free cash flow | $1.45M | $211.44M |
| Investing cash flow | -$812.65M | -$63.36M |
| Financing cash flow | $611.54M | -$421.93M |
| Depreciation & amortization | $177.74M | $161.53M |
| Stock-based compensation | $25.70M | $25.96M |
| Dividends paid | $60.27M | $63.54M |
| Share buybacks | $300.00M | $200.00M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.